Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals

S. Ohkouchi, A. Yamada, N. Imai, T. Mine, K. Harada, S. Shichijo, Y. Maeda, Y. Saijo, T. Nukiwa, K. Itoh

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


IgE-mediated type-I allergy is generally considered to be a hypersensitivity reaction to foreign antigens, and it is believed that self-antigens do not evoke this type of allergy. We report here, for the first time, that non-mutated self-antigen peptides identified as tumor-rejection antigen peptides recognized by HLA class I-restricted and tumor-specific cytotoxic T lymphocytes (CTLs) elicited a type-I allergy in the majority of healthy individuals. Peptide-specific IgE was detectable in sera from certain cases, although the levels did not always correlate with those of type-I allergy. Repeated vaccinations of nonallergic peptides derived from the same antigens possessing allergic peptides resulted in the suppression of both allergic peptide-specific IgE responses and type-I allergy, providing evidence for a new approach to the development of peptide-based desensitization.

Original languageEnglish
Pages (from-to)259-272
Number of pages14
JournalTissue Antigens
Issue number4
Publication statusPublished - 2002


  • Autoantibody
  • Autoantigen
  • Cytotoxic T-lymphocytes
  • Immediate-hypersensitivity
  • Peptides

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Genetics


Dive into the research topics of 'Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals'. Together they form a unique fingerprint.

Cite this